Evidence map›Paper›PMID 26954372›Full record

ArticleAntiviral therapy2016

Tenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.

James M Mikula, Maura M Manion, Frank Maldarelli, Lucila M Suarez, Jaha F Norman-Wheeler, Alex G Ober, Robin L Dewar, Jeffrey B Kopp, H Clifford Lane, Alice K Pau

Open access · bronzeAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

James M MikulaClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Maura M ManionNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Frank MaldarelliHIV Drug Resistance Program, National Cancer Institute, Bethesda, MD, USA.
Lucila M SuarezNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Jaha F Norman-WheelerClinical Center, NIH, Bethesda, MD, USA.
Alex G OberNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Robin L DewarApplied and Developmental Research Directorate, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Jeffrey B KoppNational Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA.
H Clifford LaneNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
Alice K PauNational Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA.
National Institute of Allergy and Infectious Diseases · USFrederick National Laboratory for Cancer Research · USLeidos (United States) · USNational Cancer Institute · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNational Institutes of Health · USNational Institutes of Health Clinical Center · US

Funding

Pathogenesis and Treatment of HIV InfectionZIAAI000585 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LANE, CLIFFORD · 2009 to 2025
$26.8M
HIV-1 Genetic Variation in Infected IndividualsZIABC010819 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MALDARELLI, FRANK · 2009 to 2025
$9.9M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 AI999999NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

We describe a patient with two recent episodes of tenofovir disoproxil fumarate (TDF)-associated acute kidney injury and six-class drug-resistant HIV infection who achieved and maintained viral suppression without worsening kidney function on a regimen including tenofovir alafenamide (TAF) through 48 weeks of therapy. The safety and efficacy of TAF in patients with TDF-associated renal tubulopathy and multiple drug resistant HIV has not yet been described. TAF may represent a useful option to maximally suppress HIV in patients with these complications.

Indexed as

Acute Kidney InjuryAdenineAlanineAnti-HIV AgentsDrug Resistance, Multiple, ViralHIV-1HIV InfectionsHumansMaleMiddle AgedSalvage TherapyTenofovirAdenineAlanineAnti-HIV AgentsTenofovirtenofovir alafenamide

Identifiers

PMID26954372
PMCPMC5016206
OpenAlexW2319850419

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.